알지노믹스

476830KOSDAQ

53.8 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment20.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 11.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aljonoomics is a biotech company that develops new drugs using platform technology, leveraging RNA trans-splicing ribozyme to target and replace specific RNA sequences with therapeutic genes. The company generates revenue through technology licensing and focuses on developing gene therapy treatments for genetic diseases and cancer, including hepatocellular carcinoma.

Number of Employees

39people

Average Salary

193.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

13.65Industry Average 1.200.0Point

11.4x industry avg (risky)

ROE

—Industry Average 8.003.5Point

Debt Ratio

1.62Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.8% (2-year basis)

ROE Trend

2.0 / 4

Detailed News Sentiment

11 totalPositive 10Neutral 0Negative 1Average Sentiment Score 83.2

Positive
알지노믹스 "원형RNA 생산기술, 국제학술지 게재"
알지노믹스의 원형RNA 생산 기술이 국제 학술지에 게재되어 차세대 RNA 치료제 개발에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
알지노믹스, 생산 효율 최대 7배 높인 원형 RNA 원천기술 개발
알지노믹스의 원형 RNA 기술 개발로 생산 효율이 획기적으로 향상되어 시장 경쟁력이 강화될 것으로 예상됩니다.
Negative
코스닥 투자는 '깜깜이 투자'? 증권사 보고서 기근 심각
코스닥 투자자들의 정보 접근성 부족으로 인해 투자 환경이 악화되고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 28,650Won52-week high 236,00052-week low 20,600

1-month return1.0Point

1m -11.57% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-08-19
Neutral반기보고서 (2026.06)2026-08-13